转移性乳腺癌

Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007;21:257-272. 摘要

Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475-95.全文  摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].全文

Rugo HS, Rumble B, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 Sep 1;34(25):3069-103.全文  摘要

Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010 Aug;123(1):9-24. 摘要

Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol. 2017 Dec 10;35(35):3978-86.全文  摘要

1. Edge SB, Byrd DR, Brookland RK, et al (eds). AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.

2. Leone BA, Romero A, Rabinovich MG, et al. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis: the GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol. 1988 Dec;11(6):618-22. 摘要

3. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007;21:257-272. 摘要

4. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.全文  摘要

5. World Health Organization International Agency for Research on Cancer. Cancer today. 2020 [internet publication].全文

6. National Cancer Institute (US). Cancer stat facts: female breast cancer [internet publication].全文

7. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022 Nov;72(6):524-41.全文  摘要

8. Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-15.全文  摘要

9. Gogate A, Wheeler SB, Reeder-Hayes KE, et al. Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030. JNCI Cancer Spectr. 2021 Jul 13;5(4):pkab063.全文  摘要

10. Valachis A, Carlqvist P, Ma Y, et al. Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. Br J Cancer. 2022 Sep;127(4):720-5.全文  摘要

11. Gomes I, Aguiar P, Miranda A, et al. Overall survival of patients with locoregional and metastatic breast cancer: is the influence of baseline characteristics the same? Anticancer Res. 2019 Sep;39(9):5135-42.全文  摘要

12. Zeichner SB, Herna S, Mani A, et al. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat. 2015 Oct;153(3):617-24. 摘要

13. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33.全文  摘要

14. American Society of Clinical Oncology. Breast cancer - metastatic: statistics. Jan 2022 [internet publication].全文

15. Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids. 2003 Nov;68(10-13):953-64. 摘要

16. Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021 Jan;124(1):13-26.全文  摘要

17. Layman R, Olson K, Van Poznak C. Bisphosphonates for breast cancer: questions answered, questions remaining. Hematol Oncol Clin North Am. 2007 Apr;21(2):341-67. 摘要

18. Villarreal-Garza C, Ferrigno AS, De la Garza-Ramos C, et al. Clinical utility of genomic signatures in young breast cancer patients: a systematic review. NPJ Breast Cancer. 2020;6:46.全文  摘要

19. Blok EJ, Bastiaannet E, van den Hout WB, et al. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev. 2018 Jan;62:74-90.全文  摘要

20. Lemij AA, Baltussen JC, de Glas NA, et al. Gene expression signatures in older patients with breast cancer: A systematic review. Crit Rev Oncol Hematol. 2023 Jan;181:103884.全文  摘要

21. Eisen A, Irwin E. Review: breast cancer is associated with a family history of the disease in first degree relatives. Evid Based Nurs. 2002 Jul;5(3):89.全文  摘要

22. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010 May;12(5):245-59.全文  摘要

23. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic [internet publication].全文

24. Pouptsis A, Swafe L, Patwardhan M, et al. Surgical and systemic treatment of hereditary breast cancer: a mini-review with a focus on BRCA1 and BRCA2 mutations. Front Oncol. 2020 Oct 20;10:553080.全文  摘要

25. Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475-95.全文  摘要

26. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].全文

27. Carlson RW, Brown E, Burstein HJ, et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26. 摘要

28. Amin MB, Edge S, Greene F, et al (eds). American Joint Committee on Cancer (AJCC) cancer staging manual. 8th ed (3rd printing). Chicago: Springer International Publishing; 2018.

29. Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994 Jan;24(1):41-7. 摘要

30. Piccart M, van 't Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021 Apr;22(4):476-88. 摘要

31. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018 Jul 12;379(2):111-21.全文  摘要

32. Lænkholm AV, Jensen MB, Eriksen JO, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018 Mar 10;36(8):735-40.全文  摘要

33. Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006;24:2261-2267.全文  摘要

34. Landemaine T, Jackson A, Bellahcène A, et al. A six-gene signature predicting breast cancer lung metastasis. Cancer Res. 2008 Aug 1;68(15):6092-9.全文  摘要

35. Savci-Heijink CD, Halfwerk H, Koster J, et al. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016 Apr;156(2):249-59.全文  摘要

36. Brasó-Maristany F, Paré L, Chic N, et al. Gene expression profiles of breast cancer metastasis according to organ site. Mol Oncol. 2022 Jan;16(1):69-87.全文  摘要

37. Sheehan M, Heald B, Yanda C, et al. Investigating the link between Lynch syndrome and breast cancer. Eur J Breast Health. 2020 Apr;16(2):106-9.全文  摘要

38. Kleiblova P, Stolarova L, Krizova K, et al. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019 Oct 1;145(7):1782-97.全文  摘要

39. Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021 Feb 4;384(5):428-39.全文  摘要

40. Moslemi M, Moradi Y, Dehghanbanadaki H, et al. The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021 Jan 5;21(1):27.全文  摘要

41. Deck MD, Henschke C, Lee BC, et al. Computed tomography versus magnetic resonance imaging of the brain. A collaborative interinstitutional study. Clin Imaging. 1989;13:2-15. 摘要

42. Rossi S, Basso M, Strippoli A, et al. Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer. 2015;15:307-312. 摘要

43. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am. 2007 Jul;45(4):669-76, vi. 摘要

44. Quattrocchi CC, Piciucchi S, Sammarra M, et al. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med (Torino). 2007 Oct;112(7):1049-59. 摘要

45. Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May;5 Suppl 1:S1-22; quiz S23-2. 摘要

46. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017 Mar 10;35(8):893-911.全文  摘要

47. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66.全文  摘要

48. Henry NL, Somerfield MR, Dayao Z, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2022 Sep 20;40(27):3205-21.全文  摘要

49. Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist. 2011;16(9):1203-14.全文  摘要

50. Briest S, Stearns V. Chemotherapeutic strategies for advanced breast cancer. Oncology (Williston Park). 2007 Oct;21(11):1325-35; discussion 1338, 1340. 摘要

51. Cahan WG, Woodward HQ, Higinbotham NL, et al. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer. 1998 Jan 1;82(1):8-34.全文  摘要

52. Cufer T. Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol. 2007 Sep;18 Suppl 8:viii18-25. 摘要

53. Omuro AM, Leite CC, Mokhtari K, et al. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006 Nov;5(11):937-48. 摘要

54. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 Dec;31(12):1623-49.全文  摘要

55. West HJ, Jin JO. JAMA Oncology Patient Page. Performance status in patients with cancer. JAMA Oncol. 2015 Oct;1(7):998. 摘要

56. British Geriatrics Society. Comprehensive Geriatric Assessment (CGA) and why it is done? February 2016. http://www.bgs.org.uk/ (last accessed 17 May 2017).全文

57. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457-3465.全文  摘要

58. Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol. 2013;31:3877-3882.全文  摘要

59. Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30:1829-1834.全文  摘要

60. Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010 Feb;107(6):85-91.全文  摘要

61. Arpino G, Milano M, De Placido S. Features of aggressive breast cancer. Breast. 2015 Oct;24(5):594-600.全文  摘要

62. Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001.

63. Rugo HS, Rumble B, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 Sep 1;34(25):3069-103.全文  摘要

64. Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021 Dec 10;39(35):3959-77.全文  摘要

65. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,510 women. J Clin Oncol. 1998 Oct;16(10):3439-60. 摘要

66. McAndrew NP, Finn RS. Clinical review on the management of hormone receptor-positive metastatic breast cancer. JCO Oncol Pract. 2022 May;18(5):319-27.全文  摘要

67. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. 摘要

68. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17;375(20):1925-36.全文  摘要

69. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 Jul 1;29(7):1541-47.全文  摘要

70. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-46.全文  摘要

71. Olson SR, DeLoughery TG, Shatzel JJ. Cyclin-dependent kinase inhibitor-associated thromboembolism. JAMA Oncol. 2019 Feb 1;5(2):141-42. 摘要

72. US Food & Drug Administration. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. 13 Sep 2019 [internet publication].全文

73. Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17;388(10063):2997-3005. 摘要

74. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Aug 20;36(24):2465-72.全文  摘要

75. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020 Feb 6;382(6):514-24.全文  摘要

76. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021 Aug;32(8):1015-24.全文  摘要

77. Carlini P, Bria E, Giannarelli D, et al. Aromatase inhibitors in post-menopausal metastatic breast carcinoma. Expert opinion on investigational drugs. Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. 摘要

78. Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010 Aug;123(1):9-24. 摘要

79. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003370.全文  摘要

80. Moy B, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Jan 10;JCO2202807. [Epub ahead of print].全文  摘要

81. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9.全文  摘要

82. Pritchard KI, Burris HA 3rd, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013 Dec;13(6):421-32.e8.全文  摘要

83. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct 25;30(10):870-84.全文  摘要

84. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209-19.全文  摘要

85. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39. 摘要

86. Valachis A, Mauri D, Polyzos NP, et al. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2010 Mar;73(3):220-7. 摘要

87. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017 Sep 1;35(25):2875-84.全文  摘要

88. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018 Nov 15;379(20):1926-36.全文  摘要

89. Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020 Jan 1;6(1):116-24.全文  摘要

90. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019 May 16;380(20):1929-40. 摘要

91. André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021 Feb;32(2):208-17.全文  摘要

92. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000 Apr;18(7):1399-411. 摘要

93. Stebbing J, Ngan S. Breast cancer (metastatic). BMJ Clin Evid. 2010 Sep 8;2010:0811.全文  摘要

94. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 15;379(8):753-63.全文  摘要

95. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Jun 4;377(6):523-33.全文  摘要

96. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-24.全文  摘要

97. Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar;16(3):994-9. 摘要

98. Boccardo F, Rubagotti A, Perotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 1994 Apr;5(4):337-42. 摘要

99. Crump M, Sawka CA, DeBoer G, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 1997 Jul;44(3):201-10. 摘要

100. Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada clinical trials group trial MA1. Breast Cancer Res Treat. 1997 Jul;44(3):211-5. 摘要

101. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-15. 摘要

102. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019 Jul 25;381(4):307-16.全文  摘要

103. Giordano SH, Franzoi MAB, Temin S, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022 Aug 10;40(23):2612-35.全文  摘要

104. Baselga J, Cortés J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19.全文  摘要

105. Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34.全文  摘要

106. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-30. 摘要

107. Drucker AM, Wu S, Dang CT, et al. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012 Sep;135(2):347-54. 摘要

108. Tan AR, Im SA, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021 Jan;22(1):85-97. 摘要

109. Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2006;100(suppl 1):A3.

110. Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022 Mar 24;386(12):1143-54. 摘要

111. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan 14;401(10371):105-17.全文  摘要

112. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020 Feb 13;382(7):610-21.全文  摘要

113. Ramakrishna N, Anders CK, Lin NU, et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol. 2022 Aug 10;40(23):2636-55.全文  摘要

114. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020 Feb 13;382(7):597-609.全文  摘要

115. Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2022 Dec 1;e225610. [Epub ahead of print].全文  摘要

116. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43.全文  摘要

117. Rugo HS, Im SA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021 Apr 1;7(4):573-84.全文  摘要

118. Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020 Sep 20;38(27):3138-49.全文  摘要

119. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999-2006.全文  摘要

120. Gori S, Montemurro F, Spazzapan S, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jun;23(6):1436-41.全文  摘要

121. Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242.全文  摘要

122. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996 Mar;14(3):737-44. 摘要

123. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1124-30.全文  摘要

124. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20;30(21):2585-92.全文  摘要

125. Emens LA, Adams S, Cimino-Mathews A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 Aug;9(8):e002597.全文  摘要

126. Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-35.全文  摘要

127. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-66.全文  摘要

128. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-37.全文  摘要

129. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108-21.全文  摘要

130. ClinicalTrials.gov (US). A study of atezolizumab and paclitaxel versus placebo and paclitaxel in participants with previously untreated locally advanced or metastatic triple negative breast cancer (TNBC) (IMpassion131). Feb 2022 [internet publication].全文

131. US Food and Drug Administration. FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer. 8 Sep 2020 [internet publication].全文

132. European Medicines Agency. EMA reminds physicians to use Tecentriq with nab-paclitaxel for treating breast cancer. Oct 2020 [internet publication].全文

133. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec 5;396(10265):1817-28. 摘要

134. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr 22;384(16):1529-41.全文  摘要

135. Cardoso F, Bedard PL, Winer EP, et al; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009 Sep 2;101(17):1174-81.全文  摘要

136. Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003372.全文  摘要

137. Chlebowski RT, Smalley RV, Weiner JM, et al. Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. Br J Cancer. 1989 Feb;59(2):227-30. 摘要

138. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 1998 Dec;16(12):3720-30. 摘要

139. Cianfrocca M, Gradishar WJ. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer. J Natl Compr Canc Netw. 2007 Sep;5(8):673-5. 摘要

140. Conlin AK, Seidman AD. Point: combination versus single-agent chemotherapy: the argument for sequential single agents. J Natl Compr Canc Netw. 2007 Sep;5(8):668-72. 摘要

141. Ghersi D, Willson ML, Chan MM, et al. Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2015 Jun 10;(6):CD003366.全文  摘要

142. O’Shaughnessy J, Gradishar WJ, Bhar P, et al. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat. 2013 Apr;138(3):829-37.全文  摘要

143. O'Brien ME, Wigler N, Inbar M, et al; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9. 摘要

144. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007 Aug 10;25(23):3407-14.全文  摘要

145. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. 摘要

146. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7.全文  摘要

147. Kardinal C, Cole J. Breast cancer. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008.

148. Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol. 2017 Dec 10;35(35):3978-86.全文  摘要

149. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017 Jan - Feb;7(1):4-12.全文  摘要

150. Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020 Dec;31(12):1650-63.全文  摘要

151. US Food and Drug Administration. FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab). Nov 2022 [internet publication].全文

152. Ruiterkamp J, Voogd AC, Bosscha K, et al. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat. 2010 Feb;120(1):9-16. 摘要

153. Tosello G, Torloni MR, Mota BS, et al. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 2018 Mar 15;(3):CD011276.全文  摘要

154. O'Shaughnessy J. BSI-201 phase II data in metastatic triple-negative breast cancer. Plenary Session, ASCO Annual Meeting, 31 May 2009.

155. Moy B, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for human epidermal growth factor receptor 2-negative metastatic breast cancer that Is either endocrine-pretreated or hormone receptor-negative: ASCO guideline rapid recommendation pdate. J Clin Oncol. 2022 Sep 10;40(26):3088-90.全文  摘要

156. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022 Jul 7;387(1):9-20.全文  摘要

157. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10;31(17):2128-35. 摘要

158. ClinicalTrials.gov. Ph3 study of exemestane with or without entinostat in chinese patients with hormone receptor-positive, locally advanced or metastatic breast cancer. ClinicalTrials.gov identifier: NCT03538171. Jul 2021 [internet publication].全文

159. ​ClinicalTrials.gov. Entinostat in patients with recurrent advanced hormone receptor-positive breast cancer. ClinicalTrials.gov identifier: NCT02115282. Nov 2021 [internet publication].全文

160. ​ClinicalTrials.gov. Study of elacestrant in combination with onapristone in patients with advanced or metastatic breast cancer (ELONA). ClinicalTrials.gov identifier: NCT05618613. Jan 2023 [internet publication].全文

161. ClinicalTrials.gov. ​Phase Ib/II trial of abemaciclib and elacestrant in patients with brain metastasis due to HR+/Her2- breast cancer. ClinicalTrials.gov identifier: NCT04791384. May 2022 [internet publication].全文

162. ​ClinicalTrials.gov. Study of abemaciclib and elacestrant in patients with brain metastasis due to HR+/HER2- breast cancer (ELECTRA). ClinicalTrials.gov identifier: NCT05386108. Jan 2023 [internet publication].全文

163. Klar N, Rosenzweig M, Diergaarde B, et al. Features associated with long-term survival in patients with metastatic breast cancer. Clin Breast Cancer. 2019 Aug;19(4):304-10. 摘要

164. Leone JP, Leone J, Vallejo CT, et al. ​Factors associated with short- and long-term survival in metastatic HER2+ breast cancer. J Clin Oncol. 2022 40:16_suppl, 1047 [Epub ahead of print].全文

165. Cancer Research UK. Breast cancer survival by stage at diagnosis. Nov 2019 [internet publication].全文

166. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91.全文  摘要